Sagimet Biosciences Series A (SGMT) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sagimet Biosciences Series A (SGMT) has outperformed Zevra Therapeutics (ZVRA) over the past year, gaining 22.0% versus a gain of 3.4%. Zevra Therapeutics is the larger company by market cap ($676.4 million vs $633.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SGMT | ZVRA |
|---|---|---|
| Share price | $8.93 | $11.39 |
| Market cap | $633.21M | $676.38M |
| 1-day change | +0.11% | +3.55% |
| YTD return | +50.68% | +22.77% |
| 1-year return | +22.02% | +3.38% |
| 5-year return | — | +12.59% |
| P/E ratio (TTM) | — | 12.38 |
| Forward P/E | — | 10.58 |
| EPS (TTM) | $-1.27 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.45 | $15.04 |
| 52-week low | $4.50 | $8.01 |
| Distance from 52-week high | -22.00% | -24.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +212.54% | +119.49% |
| Average volume | 1.24M | 1.11M |
| Shares outstanding | 70.34M | 59.38M |
| Employees | 16 | 61 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SGMT has outperformed ZVRA by 18.6 percentage points over the past year.
About Sagimet Biosciences Series A
SGMT stock →Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees
SGMT vs ZVRA FAQ
Which is bigger, Sagimet Biosciences Series A or Zevra Therapeutics?
Zevra Therapeutics (ZVRA) is larger, with a market capitalization of $676.38M compared with $633.21M for Sagimet Biosciences Series A (SGMT).
Which stock has performed better over the past year, SGMT or ZVRA?
SGMT returned +22.02% over the past 12 months, compared with +3.38% for ZVRA (price return, excluding dividends). Past performance does not predict future results.
Are Sagimet Biosciences Series A and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.